ALEXION PHARMACEUTICALS, INC. Insider Trading for March 2016
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ALEXION PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in ALEXION PHARMACEUTICALS, INC. for March 2016.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 04 2016 | ALXN | ALEXION PHARMACEUT ... | O'Neill Julie | EVP. Global Operati ... | Sell | S | 149.55 | 651 | 97,357 | 36,034 | 36.7 K to 36 K (-1.77 %) |
| Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Wagner Heidi L | SVP, Global Governm ... | Option Exercise | A | 140.16 | 21,000 | 2,943,360 | 21,000 | |
| Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Wagner Heidi L | SVP, Global Governm ... | Sell | S | 138.91 | 547 | 75,984 | 32,390 | 32.9 K to 32.4 K (-1.66 %) |
| Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Wagner Heidi L | SVP, Global Governm ... | Grant | A | 0.00 | 3,000 | 0 | 32,937 | 29.9 K to 32.9 K (+10.02 %) |
| Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | EVP, Chief Commerci ... | Option Exercise | A | 140.16 | 31,000 | 4,344,960 | 31,000 | |
| Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | EVP, Chief Commerci ... | Sell | S | 138.91 | 54 | 7,501 | 41,579 | 41.6 K to 41.6 K (-0.13 %) |
| Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Thiel Carsten | EVP, Chief Commerci ... | Grant | A | 0.00 | 5,000 | 0 | 41,633 | 36.6 K to 41.6 K (+13.65 %) |
| Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | MACKAY MARTIN | EVP & Global Head o ... | Option Exercise | A | 140.16 | 31,000 | 4,344,960 | 31,000 | |
| Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | MACKAY MARTIN | EVP & Global Head o ... | Sell | S | 138.91 | 1,000 | 138,910 | 46,785 | 47.8 K to 46.8 K (-2.09 %) |
| Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | MACKAY MARTIN | EVP & Global Head o ... | Grant | A | 0.00 | 7,000 | 0 | 47,785 | 40.8 K to 47.8 K (+17.16 %) |
| Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Miller Edward | SVP, Chief Complian ... | Option Exercise | A | 140.16 | 21,000 | 2,943,360 | 21,000 | |
| Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Miller Edward | SVP, Chief Complian ... | Sell | S | 138.91 | 329 | 45,701 | 16,886 | 17.2 K to 16.9 K (-1.91 %) |
| Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Miller Edward | SVP, Chief Complian ... | Grant | A | 0.00 | 3,000 | 0 | 17,215 | 14.2 K to 17.2 K (+21.10 %) |
| Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Islam Saqib | EVP, Chief Strat & ... | Sell | S | 138.91 | 905 | 125,714 | 43,799 | 44.7 K to 43.8 K (-2.02 %) |
| Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Option Exercise | A | 140.16 | 31,000 | 4,344,960 | 31,000 | |
| Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Sell | S | 141.23 | 2 | 282 | 178,740 | 178.7 K to 178.7 K (0.00 %) |
| Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Sell | S | 138.91 | 1,120 | 155,579 | 178,742 | 179.9 K to 178.7 K (-0.62 %) |
| Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Sinha Vikas | EVP & CFO | Grant | A | 0.00 | 8,000 | 0 | 179,862 | 171.9 K to 179.9 K (+4.65 %) |
| Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | O'Neill Julie | EVP. Global Operati ... | Option Exercise | A | 140.16 | 31,000 | 4,344,960 | 31,000 | |
| Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | O'Neill Julie | EVP. Global Operati ... | Sell | S | 138.91 | 663 | 92,097 | 36,685 | 37.3 K to 36.7 K (-1.78 %) |
| Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | O'Neill Julie | EVP. Global Operati ... | Grant | A | 0.00 | 7,000 | 0 | 37,348 | 30.3 K to 37.3 K (+23.07 %) |
| Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | EVP & General Couns ... | Option Exercise | A | 140.16 | 31,000 | 4,344,960 | 31,000 | |
| Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | EVP & General Couns ... | Sell | S | 140.65 | 1 | 141 | 52,278 | 52.3 K to 52.3 K (0.00 %) |
| Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | EVP & General Couns ... | Sell | S | 138.91 | 1,200 | 166,692 | 52,279 | 53.5 K to 52.3 K (-2.24 %) |
| Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Moriarty John B | EVP & General Couns ... | Grant | A | 0.00 | 5,000 | 0 | 53,479 | 48.5 K to 53.5 K (+10.31 %) |
| Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | EVP, Chief HR Offic ... | Option Exercise | A | 140.16 | 31,000 | 4,344,960 | 31,000 | |
| Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | EVP, Chief HR Offic ... | Sell | S | 138.91 | 1,312 | 182,250 | 39,742 | 41.1 K to 39.7 K (-3.20 %) |
| Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Carmichael Clare | EVP, Chief HR Offic ... | Grant | A | 0.00 | 7,000 | 0 | 41,054 | 34.1 K to 41.1 K (+20.56 %) |
| Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Hallal David | CEO | Option Exercise | A | 140.16 | 131,000 | 18,360,960 | 131,000 | |
| Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Hallal David | CEO | Sell | S | 141.45 | 14 | 1,980 | 191,012 | 191 K to 191 K (-0.01 %) |
| Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Hallal David | CEO | Sell | S | 138.91 | 2,000 | 277,820 | 191,026 | 193 K to 191 K (-1.04 %) |
| Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | Hallal David | CEO | Grant | A | 0.00 | 20,000 | 0 | 193,026 | 173 K to 193 K (+11.56 %) |
| Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 140.58 | 25 | 3,515 | 742,197 | 742.2 K to 742.2 K (0.00 %) |
| Mar 01 2016 | ALXN | ALEXION PHARMACEUT ... | BELL LEONARD | Director | Sell | S | 138.91 | 3,970 | 551,473 | 742,222 | 746.2 K to 742.2 K (-0.53 %) |